Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update

Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine cli...

Full description

Saved in:
Bibliographic Details
Published inEndocrinologia, diabetes y nutricion Vol. 65; no. 10; p. 611
Main Authors Gomez-Peralta, Fernando, Escalada San Martín, Francisco Javier, Menéndez Torre, Edelmiro, Mata Cases, Manel, Ferrer García, Juan Carlos, Ezkurra Loiola, Patxi, Ávila Lachica, Luis, Fornos Pérez, Jose Antonio, Artola Menéndez, Sara, Álvarez-Guisasola, Fernando, Rica Echevarría, Itxaso, Girbés Borrás, Juan
Format Journal Article
LanguageEnglish
Published Spain 01.12.2018
Subjects
Type 2 diabetes
Hypoglycaemia
Diabetes tipo 2
Hipoglucemia
Cost
Complexity
Nefroprotección
Treatment
Cardiovascular risk
Riesgo cardiovascular
Nephroprotection
Tratamiento
Complejidad
Coste
Online AccessGet more information

Cover

More Information
Summary:Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine clinical practice and have changed the algorithm of DM2 pharmacological therapy. Therefore, the Spanish Society of Diabetes (SED) entrusted to the Working Group of Consensus and Clinical Guidelines an update of the 2010 document Recommendations for Pharmacological Treatment of Hyperglycemia in Diabetes type2. Novel aspects include nine characteristics to describe each drug group: efficiency, the risk of hypoglycemia, effects on body weight, the demonstrated effect in cardiovascular risk, nephroprotection, limitation of use in renal insufficiency, the rate of secondary effects, complexity and costs. Additionally, the document details combination options, and develop the start and adjustment of available injectable therapies.
ISSN:2530-0172
DOI:10.1016/j.endinu.2018.08.004